Displaying 198 (all) recruiting clinical trials.
-
Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome: A COG Groupwide Phase III Study
The purpose of the trial is to determine the safety and efficacy of the standard treatment for children diagnosed with Acute Myeloid Leukemia (AML) or ... -
A Phase 3 Trial Investigating Blinatumomab (IND#117467 NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma(B-LLy)
The purpose of the trial is to determine the safety and efficacy of the investigational medicine, blinatumomab plus standard treatment for patients who have Standard ... -
ACNS1831: A Phase 3 Randomized Study of Selumetinib (IND # 77782) versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
The purpose of the study is to compare the efficacy of two treatments. The purpose is to determine whether the efficacy of treatment with selumetinib ... -
AALL1931: JZP458-201: An Open Label Multicenter Study of RC-P in Patients with Acute Lymphoblastic Leukemia ALL/Lymphoblastic Lymphoma LBL Following Hypersensitivity to E. coli-derived Asparaginases
The purpose of the study is to learn more about the pharmacology or how your body handles Recombinant Crisantaspase produced in Pseudomonas fluorescens or RC-P ... -
Expanded Access to ONC201 for Patients with H3 K27M-mutant and/or Midline Gliomas
The purpose of this research study is to provide ONC201 to patients with specific forms of brain cancer who cannot access ONC201 by participating in ... -
AALL1732 A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494 NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL Mixed Phenotype Acute Leukemia and Disseminated B-LLy
The purpose of the study is to determine the safety and efficacy of the investigational medicine Inotuzumab Ozogamicin for patients who have NCI high risk ... -
A PHASE IB-II STUDY OF HIGH-DOSE POST-TRANSPLANT CYCLOPHOSPHAMIDE BORTEZOMIB ABATACEPT AND SHORT-DURATION TACROLIMUS FOR THE PREVENTION OF GRAFT-VERSUS-HOST DISEASE (GVHD) FOLLOWING HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
The purpose of the study is to determine the safety and efficacy of cyclophosphamide, abatacept, and short-duration tacrolimus for GvHD prophylaxis following haploidentical hematopoietic stem ... -
AHEP1531: Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
This trial is the first international cooperative liver tumors trial in which a consensus approach was established by investigators representing Children’s Oncology Group (COG ... -
AALL1732: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494 NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL Mixed Phenotype Acute Leukemia and Disseminated B-LLy
The primary aim of this study is to assess in a randomized fashion whether or not the incorporation of two cycles of inotuzumab ozogamicin (InO ... -
An Open-label Single-arm Single-dose Prospective Multicenter Phase 3 Study to Establish the Diagnostic Performance of 18F-Fluciclovine Positron Emission Tomography (PET) in Detecting Recurrent Brain Metastases after Radiation Therapy
The purpose of the study is to determine the diagnostic performance of 18F-Fluciclovine Positron Emission Tomography (PET) in detecting recurrent brain metastases after radiation therapy ...